Evidity Health Capital

GT Medical Technologies, Inc. is a medical device company based in Tempe, Arizona, dedicated to improving the lives of patients with brain tumors. Founded in 2017, the company has developed an innovative treatment approach through its flagship product, GammaTile, which combines a biocompatible, conformable collagen matrix with brachytherapy radiation seeds. This technology is designed to address the limitations of existing treatments for recurrent brain tumors, providing a bioresorbable solution that enhances treatment efficacy. GammaTile is protected by multiple patents and has the potential to benefit a significant patient population, with an estimated 176,000 patients diagnosed annually in the United States. To date, clinical trials at Barrow Neurological Institute have demonstrated promising outcomes, with significant clinical improvements observed in patients treated with this novel device.

Augmedics Ltd. is a company that specializes in augmented reality surgical guidance systems, aiming to enhance the safety and effectiveness of surgical procedures. Founded in 2014 and headquartered in Yoqneam Ilit, Israel, with an additional office in Chicago, Illinois, the company has developed the xvision-spine (XVS) system. This innovative system features a head-mounted display that allows surgeons to visualize a patient's anatomy through skin and tissue, providing real-time insights into the position of surgical tools and illuminating the surgical area. By integrating advanced technologies, Augmedics seeks to transform surgical treatment and improve patient outcomes during complex operations.

PreludeDx develops molecular diagnostics and personalized medicine specifically for early-stage breast cancer, aiming to enhance decision-making for patients and physicians. Founded in 2009 and based in Laguna Hills, California, the company leverages technology licensed from the University of California San Francisco to create innovative tools that influence treatment options. One of its primary offerings is The DCISionRT, a test that predicts the potential benefit of radiation therapy for patients with ductal carcinoma in situ. By incorporating advancements in molecular biology, artificial intelligence, and machine learning, PreludeDx seeks to improve patient outcomes and reduce healthcare costs associated with breast cancer treatment.

Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Sonde Health is a digital medicine company focused on developing voice-based technologies for monitoring and diagnosing mental and respiratory health. The company's innovative platform utilizes mobile devices to capture and analyze subtle changes in voice, allowing for the creation of various health measurements related to brain, muscle, and respiratory function. By enabling users to track changes in their health over time, Sonde Health aims to identify early signs of disease, ultimately transforming the approach to health monitoring and diagnosis.

Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

EndoGastric Solutions, Inc. is a medical device company specializing in innovative surgical technologies aimed at treating gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, the company develops and manufactures natural orifice surgical products. Its flagship technology, EsophyX, facilitates transoral reconstructive surgery, while the EsophyX Z device is specifically designed for the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions offers SerosaFuse Fasteners, a non-resorbable polypropylene product that provides strength comparable to traditional sutures. The company also supports surgeons through training courses and a range of consultative services, including pre-authorization and medical review.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital treatments for cognitive disorders. The company's core technology involves creating video games that not only engage users but also assess and enhance cognitive abilities. Akili's pipeline focuses on treating and improving symptoms associated with various medical conditions, including ADHD, MDD, ASD, and inflammatory diseases.

Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products designed to facilitate the body's healing process after catheterization procedures. The company offers several innovative products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications. Additionally, Cardiva Medical provides the Cardiva CATALYST, a manual compression assistance device that enhances coagulation for patients requiring temporary hemostasis. Another key product is the VASCADE MVP, which is used for multi-site venous closure during electrophysiology procedures, such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers throughout the United States, focusing on transforming vascular closure practices to improve patient outcomes.

Dune Medical Devices, established in 2002, specializes in tissue characterization technology aimed at enhancing cancer detection during surgical procedures. The company has developed the MarginProbe™ System, which utilizes radiofrequency spectroscopy to provide real-time assessments of excised tissue, helping surgeons determine whether cancerous margins have been adequately removed. This innovative approach addresses a critical concern for oncological surgeons, particularly in breast cancer treatment, by enabling them to make informed decisions during surgery, thus potentially reducing the need for reoperations. In a study involving 300 breast cancer patients in Israel, the use of the MarginProbe System resulted in a 56% reduction in reoperation rates compared to standard practices. Dune Medical Devices' solutions focus on improving the cancer care experience by consistently differentiating between cancerous and healthy tissue, ultimately aiming to enhance patient outcomes.

Magnolia Medical Technologies, Inc. is a medical device company based in Seattle, Washington, focused on enhancing the accuracy of diagnostic blood culture tests. Established in 2011, the company has developed SteriPath, a vacuum-assisted blood collection system designed to prevent contamination of blood samples, which can lead to misdiagnosis of sepsis. This innovative system operates by actively diverting and sequestering contaminated blood, allowing for the collection of uncontaminated samples through a separate flow path. This closed vein-to-bottle collection method aims to improve diagnostic specimen quality, thereby increasing diagnostic accuracy and improving patient outcomes. Magnolia Medical Technologies holds a robust intellectual property portfolio, including over 70 issued patents and more than 50 pending applications, reflecting its commitment to advancing medical technology and addressing challenges such as antibiotic resistance. The company's products are distributed throughout the United States.

Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products designed to facilitate the body's healing process after catheterization procedures. The company offers several innovative products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications. Additionally, Cardiva Medical provides the Cardiva CATALYST, a manual compression assistance device that enhances coagulation for patients requiring temporary hemostasis. Another key product is the VASCADE MVP, which is used for multi-site venous closure during electrophysiology procedures, such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers throughout the United States, focusing on transforming vascular closure practices to improve patient outcomes.

Akili Interactive Labs, Inc., established in 2011 and headquartered in Boston, Massachusetts, specializes in developing digital treatments for cognitive disorders. The company's core technology involves creating video games that not only engage users but also assess and enhance cognitive abilities. Akili's pipeline focuses on treating and improving symptoms associated with various medical conditions, including ADHD, MDD, ASD, and inflammatory diseases.

Biotheranostics, Inc. is a commercial-stage molecular diagnostics company based in San Diego, California, focused on developing and providing proprietary diagnostic, prognostic, and predictive tests to support cancer treatment. The company offers a range of tests, including the Breast Cancer Index, which assists oncologists in making informed decisions about extended endocrine therapy for estrogen receptor-positive breast cancer patients. Additionally, CancerTYPE ID provides genomic information crucial for the diagnosis and treatment of metastatic cancer, while the bioT3 metastatic cancer solution integrates molecular diagnosis with comprehensive biomarker data to enhance treatment options for metastatic cancer patients. Biotheranostics operates a CLIA-certified, CAP-accredited laboratory, which is authorized to perform testing across all 50 states, positioning the company as a leader in addressing unmet medical needs in oncology. Founded in 1996, Biotheranostics was previously known as AviaraDx, Inc. and rebranded in 2008.

Tryton Medical, Inc. is a medical device company based in Durham, North Carolina, specializing in the development and manufacturing of side branch stent systems designed to treat coronary bifurcation lesions in patients with cardiovascular diseases. Founded in 2003, the company provides its innovative Tryton Side Branch Stent System, which targets atherosclerotic lesions at bifurcation sites. Tryton Medical distributes its products through a global network of distributors and also addresses investigational needs within the United States. The company's offerings are available in several countries, including Austria, Belgium, Denmark, Ireland, Luxembourg, the Netherlands, Norway, Poland, Portugal, Spain, and the United Kingdom.

Cardiva Medical, Inc. is a medical device company that specializes in vascular access management products designed to facilitate the body's healing process after catheterization procedures. The company offers several innovative products, including the VASCADE VCS, an extravascular and bioabsorbable femoral access closure system that promotes rapid hemostasis while reducing complications. Additionally, Cardiva Medical provides the Cardiva CATALYST, a manual compression assistance device that enhances coagulation for patients requiring temporary hemostasis. Another key product is the VASCADE MVP, which is used for multi-site venous closure during electrophysiology procedures, such as cardiac ablation. Founded in 2002 and headquartered in Santa Clara, California, Cardiva Medical serves physicians and cardiac centers throughout the United States, focusing on transforming vascular closure practices to improve patient outcomes.

Dune Medical Devices, established in 2002, specializes in tissue characterization technology aimed at enhancing cancer detection during surgical procedures. The company has developed the MarginProbe™ System, which utilizes radiofrequency spectroscopy to provide real-time assessments of excised tissue, helping surgeons determine whether cancerous margins have been adequately removed. This innovative approach addresses a critical concern for oncological surgeons, particularly in breast cancer treatment, by enabling them to make informed decisions during surgery, thus potentially reducing the need for reoperations. In a study involving 300 breast cancer patients in Israel, the use of the MarginProbe System resulted in a 56% reduction in reoperation rates compared to standard practices. Dune Medical Devices' solutions focus on improving the cancer care experience by consistently differentiating between cancerous and healthy tissue, ultimately aiming to enhance patient outcomes.